Does Presbyterian Healthcare Services Cover Eliquis?

How Presbyterian Healthcare Services Handles Eliquis on Its Formulary

Presbyterian Healthcare Services, headquartered in Albuquerque, New Mexico, operates commercial, Medicare Advantage, and Centennial Care (Medicaid) health plans. Each plan publishes its own formulary, and Eliquis placement can differ across them. On most Presbyterian commercial plans, apixaban sits on Tier 3, a preferred brand tier that carries a moderate copay but does not require members to try a generic alternative first in every case.

The FDA approved apixaban in December 2012 for stroke prevention in patients with nonvalvular atrial fibrillation. Since then, its label has expanded to include treatment and secondary prevention of deep vein thrombosis and pulmonary embolism, along with post-surgical thromboprophylaxis after hip or knee replacement [1]. Because these indications are well-supported by randomized trial data, most large insurers, Presbyterian included, list apixaban on their formularies rather than excluding it outright.

Presbyterian's Medicare Advantage formulary typically places Eliquis on Tier 3 as well, though Medicare Part D cost-sharing differs from commercial plans. Under the Inflation Reduction Act provisions that took effect in 2025, Medicare beneficiaries now benefit from a $2,000 annual out-of-pocket cap on Part D prescription costs, which can substantially reduce what a member pays for a high-cost brand like Eliquis over a full year [2].

For Centennial Care (New Mexico Medicaid managed by Presbyterian), apixaban coverage follows the New Mexico Human Services Department's preferred drug list. Prior authorization is common in this population, and prescribers may need to document a clinical reason why warfarin is not appropriate.

What Eliquis Costs Under a Presbyterian Plan

Out-of-pocket costs depend on your specific Presbyterian benefit design. A rough guide: commercial Tier 3 copays at Presbyterian typically range from $40 to $75 per 30-day fill, while Tier 4 (non-preferred brand) copays can reach $100 to $150. Your Summary of Benefits document or the Presbyterian member portal confirms the exact figure for your plan year.

Bristol-Myers Squibb offers a manufacturer copay assistance program for commercially insured patients. Eligible members may pay as little as $10 per month, with the program covering the remainder up to a set annual maximum [3]. This card cannot be used by Medicare, Medicaid, or Tricare beneficiaries.

For Medicare Advantage members on Presbyterian's plan, the 2025 Part D redesign changed cost-sharing math considerably. Before the cap, a patient filling brand-name Eliquis (approximate wholesale acquisition cost of $550 to $600 per month) could accumulate thousands in annual out-of-pocket spend. The $2,000 cap means that after roughly four to five months of fills at typical cost-sharing rates, the member hits the ceiling and pays nothing for the rest of the calendar year. Presbyterian also participates in the Medicare Part D manufacturer discount program, which requires Bristol-Myers Squibb to provide a discount in the coverage gap phase [2].

Patients who are uninsured or underinsured and do not qualify for manufacturer assistance should ask their prescriber about the Bristol-Myers Squibb Patient Assistance Foundation, which provides Eliquis at no cost to qualifying individuals below certain income thresholds.

Prior Authorization and Step Therapy Requirements

Presbyterian may require prior authorization for Eliquis depending on the clinical indication and plan type. The most common scenarios where PA applies include prescriptions written for indications beyond the standard FDA label, patients under 18, or Centennial Care members for whom the plan requires documentation that warfarin was tried or is contraindicated.

Step therapy is a related but distinct barrier. Some Presbyterian commercial plans use step therapy protocols that ask prescribers to demonstrate that the patient tried warfarin (or another lower-cost anticoagulant) before approving Eliquis. This requirement is not universal across all Presbyterian products. The ARISTOTLE trial (N=18,201) demonstrated that apixaban 5 mg twice daily reduced stroke or systemic embolism by 21% compared to warfarin (HR 0.79 to 95% CI 0.66 to 0.95, P<0.001 for noninferiority, P=0.01 for superiority) while also producing 31% fewer major bleeding events [4]. These data give prescribers strong clinical grounds to request a step therapy override when warfarin poses bleeding risks.

To check whether your prescription requires PA or step therapy, call Presbyterian's pharmacy benefit line or log into the member portal and search the formulary tool. Your prescriber's office can also submit a benefits investigation on your behalf.

The typical PA turnaround at Presbyterian is 24 to 72 hours for standard requests. Urgent requests, submitted when the prescriber indicates that delay could cause serious harm, must be processed within 24 hours under New Mexico insurance regulations.

Clinical Evidence Supporting Eliquis Coverage

Insurers base formulary decisions on clinical efficacy, safety, and cost data. Apixaban has one of the strongest evidence profiles among DOACs, which helps explain its broad formulary inclusion.

The ARISTOTLE trial randomized 18,201 patients with atrial fibrillation and at least one stroke risk factor to apixaban 5 mg twice daily or dose-adjusted warfarin. Apixaban reduced the primary endpoint of stroke or systemic embolism (1.27% vs. 1.60% per year) and all-cause mortality (3.52% vs. 3.94%, P=0.047) [4]. The major bleeding rate was 2.13% per year with apixaban versus 3.09% with warfarin (HR 0.69, P<0.001) [4].

For venous thromboembolism, the AMPLIFY trial (N=5,395) showed apixaban was noninferior to conventional enoxaparin/warfarin therapy for recurrent VTE (2.3% vs. 2.7%, P<0.001 for noninferiority) while causing 56% less major bleeding (0.6% vs. 1.8%, P<0.001) [5].

The 2023 ACC/AHA/ACCP/HRS atrial fibrillation guideline gives DOACs a Class I recommendation over warfarin for stroke prevention in eligible patients with AF, citing superior net clinical benefit [6]. This guideline language is often referenced by prescribers when appealing step therapy requirements that mandate warfarin first.

"DOACs are recommended over warfarin in DOAC-eligible patients with AF, based on their overall favorable risk-benefit profiles," the 2023 ACC/AHA guideline states [6]. Presbyterian's pharmacy and therapeutics committee reviews these guidelines when updating formulary placement annually.

Dr. Michael Ezekowitz, a co-principal investigator of ARISTOTLE, noted in an interview with the American College of Cardiology that "apixaban achieved what no other oral anticoagulant had done: simultaneous reductions in stroke, major bleeding, and mortality compared with warfarin" [4].

How to Appeal If Presbyterian Denies Eliquis Coverage

A coverage denial is not the final word. Presbyterian members have the right to appeal, and the process follows a structured timeline under New Mexico law and federal regulations.

Step 1: Request the denial letter. Presbyterian must issue a written explanation that includes the clinical rationale for denial and your appeal rights. Read this letter carefully. The reason matters because it determines which supporting documentation your prescriber should submit.

Step 2: Prescriber peer-to-peer review. Your doctor can request a phone conversation with Presbyterian's medical director or pharmacist reviewer. During this call, the prescriber presents clinical justification for apixaban, such as bleeding risk on warfarin (high HAS-BLED score), labile INR history, drug-drug interactions, or inability to comply with INR monitoring. Peer-to-peer conversations resolve many denials without a formal appeal.

Step 3: Internal appeal. If peer-to-peer fails, file a formal internal appeal within 180 days of the denial notice. Include the prescriber's letter of medical necessity, relevant lab results (INR records, renal function), and citations from guidelines like the 2023 ACC/AHA AF guideline [6].

Step 4: External review. If the internal appeal is denied, New Mexico law allows an independent external review by a third-party organization not affiliated with Presbyterian. This review is binding on the insurer.

For Medicare Advantage members, the appeals process follows CMS Medicare Advantage appeal rules, which include specific timeframes: 7 calendar days for standard Part D appeals and 72 hours for expedited appeals [7].

Eliquis vs. Other Blood Thinners on Presbyterian Formularies

Presbyterian's formulary includes several anticoagulant options. Understanding their comparative tier placement and clinical profiles helps you and your prescriber choose the right medication or build an appeal case.

Warfarin (generic) sits on Tier 1 at Presbyterian, with copays typically under $10. It remains effective for stroke prevention, but requires regular INR monitoring (usually every 2 to 4 weeks) and has extensive food and drug interactions. The ARISTOTLE data showed apixaban's superiority to warfarin in stroke prevention, bleeding, and mortality [4].

Xarelto (rivarelbtan) is another DOAC often placed on Tier 3. The ROCKET AF trial (N=14,264) showed rivaroxaban was noninferior to warfarin for stroke prevention (HR 0.88 to 95% CI 0.75 to 1.03, P<0.001 for noninferiority) but did not achieve superiority in the intention-to-treat analysis [8]. Major bleeding rates were similar between rivaroxaban and warfarin.

Savaysa (edoxaban), placed variably on Presbyterian formularies, showed noninferiority to warfarin in the ENGAGE AF-TIMI 48 trial (N=21,105) with lower bleeding rates for the 60 mg dose [9]. Pradaxa (dabigatran) is a direct thrombin inhibitor with a different mechanism; the RE-LY trial (N=18,113) showed the 150 mg dose was superior to warfarin for stroke prevention but had higher rates of GI bleeding [10].

If Presbyterian's formulary places one DOAC at a lower tier than Eliquis, your prescriber can document clinical reasons for preferring apixaban, such as twice-daily dosing (which provides more consistent drug levels), the superior bleeding profile demonstrated in ARISTOTLE, or specific renal dosing advantages. Apixaban's renal elimination is only 27%, making it a preferred choice in patients with moderate chronic kidney disease [1].

Tips for Reducing Your Out-of-Pocket Cost on Eliquis

Even with Presbyterian coverage, brand-name Eliquis can strain a monthly budget. Several strategies can lower what you pay.

Use the manufacturer copay card if you have commercial insurance. The Bristol-Myers Squibb Eliquis copay card can reduce your cost to $10 per month [3]. Enrollment is free and can be done online or by phone.

Ask about 90-day mail-order fills. Presbyterian's mail-order pharmacy benefit often provides a 90-day supply for the cost of two monthly copays, effectively giving you a 33% discount per pill. Check whether your plan requires you to use Presbyterian's own mail pharmacy or allows a third-party mail service.

Review your plan during open enrollment each year. Presbyterian offers multiple commercial and Medicare Advantage plan options, and formulary placement or tier cost-sharing for Eliquis can change from one benefit year to the next. Comparing plans during the annual enrollment period (October 15 to December 7 for Medicare, varies for employer-sponsored) can save hundreds of dollars annually.

If you are on Medicare and approaching the $2,000 annual out-of-pocket cap, track your spending through the Medicare.gov "My Drug Costs" tool or ask Presbyterian for a cumulative cost statement. Once you hit the cap, your cost drops to zero for the remainder of the year [2].

For patients who lose coverage or face a gap, Bristol-Myers Squibb's Patient Assistance Foundation and organizations like NeedyMeds or the HealthWell Foundation may offer temporary assistance while you re-establish coverage.